National Psoriasis Foundation


6600 SW 92nd Ave. Ste 300
Portland, OR 97223
(503) 244-7404
https://registry.fastercures.org/organization-profiles/1005.html?user=10127


   

TRAIN Inventory Profile

Mission
Strategy/Approach
Research Portfolio
Financials
Key Accomplishments
Leadership
Ask Us About
 EXPAND ALL

Mission

To drive efforts to cure psoriatic disease and improve the lives of those affected.

Strategy/Approach

By 2019 NPF intends to achieve the following goals as part of the National Psoriasis Foundation's Strategic Plan:

Accelerate discovery to cure psoriatic disease by:

  • Increasing the number of dollars invested annually by the National Institutes of Health (NIH) to more than $18 million—a 50 percent increase;
  • Increasing the number of scientists studying psoriatic disease by 50 percent to 13,500;
  • Creating a community of 1,000 people with psoriasis and psoriatic arthritis who collaborate in research;
  • Initiating annual progress reports in key areas of psoriatic disease research such as, causes, diagnosis, prevention and cures;
  • Invest 30 percent or more of annual NPF expenses in research.

Dramatically improve health outcomes for all with psoriatic disease by:

  • Increase by half the number of people receiving appropriate treatment to 77 percent of those diagnosed with moderate to severe psoriasis, and 62 percent with psoriatic arthritis;
  • Reducing from 50 to 30 percent the number of individuals who report their psoriasis and psoriatic arthritis to be a problem in everyday life;
  • Publish annual progress reports in key areas of psoriatic disease care and comorbidities;
  • Increase NPF professional membership to 1,700 health care providers.

Secure resources to achieve the mission by:

  • Generating $20 million in total revenue;
  • Maintaining a $3 million operating reserve;
  • Doubling the number of volunteers engaged with NPF mission to more than 13,200.

Research Portfolio

Research is a key objective of NPF's strategic plan, as described above. Research priorities can be summarized as follows, including summaries of related initiatives:

1. Increase the number of researchers and amount of money dedicated to psoriatic disease research:

    • Advocacy efforts on the federal level in support of psoriatic disease research and biomedical research in general
    • Active engagement with the psoriatic disease research community at conferences and hosting our own scientific meeting(s)
    • Management of a robust grants and fellowships program:
    • Discovery Grants: 1 year, $75,000, early stage projects
    • Translational Research Grants: 2 years, $200,000, translational projects
    • Early Career Research Grant: 1 year, $50,000, grad students and post-docs
    • Psoriatic Arthritis Research Grant: 2 years, $200,000, PsA research (in
    • collaboration with the Arthritis National Research Foundation)
    • Medical Dermatology Fellowships: 1 year, $50,000, medical research fellows
    • NIH-NPF Robertson Fellowship in Translational medicine: 2 years, $200,000, clinical comorbodities research


2. Increase the level of patient engagement in psoriatic disease research.

    • National Psoriasis Victor Henschel BioBank of patient and control DNA
    • Annual survey 
    • Citizen Pscientist on-line community for patients to provide data, participate in scientific process, and engage with the researchers.


3. Communicating progress in psoriatic disease research to members of the psoriatic disease community.

    • Oversee publication of the peer-reviewed Journal of Psoriasis and Psoriatic Arthritis
    • Regular research communication through web and print under the guidance of our Associate Director of Scientific Communication
    • Robust program assessment program to measure outcomes of our funded research

Financials

Fiscal year 2014, year ending 6/30/14

  • Revenue: $9,432,752
  • Assets: $7,766,193
  • Grants: $1,800,000
  • Gifts Received: $1,453,146
  • Total Expenditures: $9,099,050

Key Accomplishments

  1. More than $13M awarded in research grants and fellowships to date.
  2. Psoriasis included as one of the new diseases added to FDA's Patient Focused Drug Development Initiative in 2015. 
  3. More than 1,800 patient participants in Citizen Pscientists.

Leadership

The National Psoriasis Foundation is directed by a Board of Directors. Board members are volunteers from the community who share two things:

  • Psoriasis and/or psoriatic arthritis, either individually or through a loved one.
  • A deep, personal commitment to directing the Psoriasis Foundation toward helping people with psoriasis and psoriatic arthritis, and toward finding a cause and, ultimately, a cure or permanent method of control for these diseases.

The Board of Directors approves and evaluates the Psoriasis Foundation's long-term plans, determines the goals and provides financial oversight. The Board works with the chief executive officer to accomplish the Foundation's goals. (14 members)

NPF receives guidance from a Medical Board consisting of leading experts in the clinical care of psoriatic disease and related comorbidities. It includes composed of dermatologists, rheumatologists, and one cardiologist. (22 members)

NPF research programs receive guidance from a Scientific Advisory Committee composed of leading experts in psoriatic disease research. (15 members)

Staff

Ask Us About

  • Facilitating patient engagement in the R&D process
  • Interaction with regulatory agencies
  • Social media and communications